Blood

Vol. 148, Issue 7 Issue 7 2026
17
Articles

Articles in this Issue

NOTCHing the MSC-endothelial interplay in the HSC niche

Simón Méndez-Ferrer Aug 13, 2026 pp. 798-800 10.1182/blood.2026034119

Procr+ endothelial progenitor cells govern hematopoiesis through fine-tuning mesenchymal stem cell niche signals

Chang Xu, Xue Lv, Shangda Yang et al. Aug 13, 2026 pp. 841-855 10.1182/blood.2025031474

Abstract Hematopoietic stem cells (HSCs) rely on specialized niche cells for their maintenance, yet how these regulators functionally integrate to preserve hematopoiesis remains un...

Li C, Wu B, Li Y, et al. Loss of sphingosine kinase 2 promotes the expansion of hematopoietic stem cells by improving their metabolic fitness. <i>Blood</i> . 2022;140(15):1686-1701.

Aug 13, 2026 pp. 914-914 10.1182/blood.2026035281

Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis

Karthik Chetlapalli, Satoko Ito, Ding Quan Ng et al. Aug 13, 2026 pp. 896-909 10.1182/blood.2025032290

Abstract Nonmyeloablative-related haploidentical allogeneic stem cell transplantation (NMAC-HID allo-HSCT) has emerged as an additional treatment to achieve durable remission in si...

Granulopoiesis under attack by mutant IDH1

Hideyo Hirai Aug 13, 2026 pp. 801-802 10.1182/blood.2026034486

Abro B, Maurer MJ, Habermann TM, et al. Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis. <i>Blood</i> . 2024;144(19):2063-2066.

Aug 13, 2026 pp. 914-914 10.1182/blood.2026035289

<i>IDH2</i> clonal hematopoiesis and IKAROS loss cooperate in a B-ALL subtype after lenalidomide therapy for multiple myeloma

Johanna M. Horns, Thomas Beder, Axel Künstner et al. Aug 13, 2026 pp. 856-866 10.1182/blood.2025031047

Abstract Lenalidomide, a maintenance treatment in multiple myeloma first-line therapy, increases the risk of secondary malignancies, including B-cell precursor acute lymphoblastic...

Mutant IDH1 blocks neutropoiesis by repressing myeloid progenitor programs

Mariam Hakobyan, Jens Langstein, María José Ramos Medina et al. Aug 13, 2026 pp. 867-881 10.1182/blood.2025031268

Abstract IDH1 and IDH2 are frequently mutated in various cancers, including acute leukemias. However, the distinct mechanisms by which mutant IDH1 or IDH2 drive hematopoietic neopl...

IKAROS descent and rise of lenalidomide-associated B-ALL

Benjamin Diamond Aug 13, 2026 pp. 800-801 10.1182/blood.2026033360

Dissecting polycomb complexes for enhanced fetal hemoglobin production

Paul J. Kaminski, Kristen Min, Elizabeth A. Traxler et al. Aug 13, 2026 pp. 882-895 10.1182/blood.2026033804

Abstract Polycomb repressive complex 1 (PRC1) and PRC2 regulate diverse developmental processes, including the fetal-to-adult switch in hemoglobin (Hb) production, a process whose...

Precision targeting of fetal hemoglobin repressors

Merlin Crossley Aug 13, 2026 pp. 803-804 10.1182/blood.2026034687

How I utilize somatic alterations in the diagnosis, risk stratification, and therapy of hypocellular bone marrow failure

Emma M. Groarke, Fernanda Gutierrez-Rodrigues, Bhavisha A. Patel Aug 13, 2026 pp. 818-830 10.1182/blood.2025029923

Abstract Hypocellular bone marrow failure (BMF) may be acquired due to immune-mediated disease, the prototype being immune aplastic anemia (IAA), or inherited, due to germ line def...

Pound wise, penny foolish: improving value in SCD care

Amar H. Kelkar, Joseph H. Antin Aug 13, 2026 pp. 804-806 10.1182/blood.2026034367

Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease

Dian Zhou, Yuekun Qi, Sha Ma et al. Aug 13, 2026 pp. 831-840 10.1182/blood.2026033506

Abstract Patients with relapsed or refractory multiple myeloma (RRMM) with extraosseous extramedullary disease (EMD) have inferior outcomes and lack effective therapies. We develop...

Bispecific CAR T for extramedullary myeloma: a minute waltz

Hamza Hashmi, Sham Mailankody Aug 13, 2026 pp. 797-798 10.1182/blood.2026034568

Biosimilars approved for hematology use: lessons from comparative efficacy studies and comparative analytical assessments

Thomas M. Herndon, Nina N. Brahme, M. Stacey Ricci Aug 13, 2026 pp. 807-817 10.1182/blood.2025031673

Abstract Biosimilars used in hematology have been at the forefront of biosimilar development since the first US approval in 2015 of a filgrastim product, with &amp;gt;80 now licens...

ELN-DAVID recommendations for NGS-based <i>FLT3</i> -ITD MRD testing for patients with acute myeloid leukemia

Christopher S. Hourigan, Lisanne Beugelink, Jad Othman et al. Aug 13, 2026 pp. 910-913 10.1182/blood.2026033569

Abstract FLT3-internal tandem duplication measurable residual disease testing for patients in remission from acute myeloid leukemia is now recommended by the recently updated clini...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page